Elifnaz Celik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elifnaz Celik has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
- Gizem Dinler Doganay
Department of Molecular Biology and Genetics, Istanbul Technical University, Istanbul, Turkey
3 shared publications - Izzet Mehmet Akcay
Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s College London, London, UK
3 shared publications - Levent Doganay
Genomic Laboratory (GLAB), Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
3 shared publications - Carlo Rivolta
Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, 4031, Switzerland
2 shared publications Fikret Ezberci
Department of General Surgery Umraniye Teaching and Research Hospital, University of Health Sciences Istanbul Turkey
2 shared publications- Mathieu Quinodoz
Ophthalmic Genetics Group, Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland
2 shared publications
Latest Publications
- Open Access
- 8 February 2026
- Published by Springer Nature in Human Genomics
- Vol. 20 (1)
Variant reclassification in cancer susceptibility genes and an updated variant spectrum of Turkish breast and colorectal cancer patients
The online version contains supplementary material available at 10.1186/s40246-026-00915-0.
- 8 February 2026
- Published by Springer Nature in Human Genomics
- Vol. 20 (1)
Open AccessVariant reclassification in cancer susceptibility genes and an updated variant spectrum of Turkish breast and colorectal cancer patients
The online version contains supplementary material available at 10.1186/s40246-026-00915-0.
- Open Access
- 25 March 2024
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 111 (4) , 701-713
Detection of elusive DNA copy-number variations in hereditary disease and cancer through the use of noncoding and off-target sequencing reads
- 25 March 2024
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 111 (4) , 701-713
Open AccessDetection of elusive DNA copy-number variations in hereditary disease and cancer through the use of noncoding and off-target sequencing reads
- Open Access
- 3 November 2022
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 18 (11) , e1010367
Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative
Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75–10.05, p = 5.41x10-7). This association was consistent across sexes. These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.
- 3 November 2022
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 18 (11) , e1010367
Open AccessExome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative
Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75–10.05, p = 5.41x10-7). This association was consistent across sexes. These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.
- 13 July 2020
- Published by Wiley in International Journal of Cancer
- Vol. 148 (2) , 285-295
Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls
Inherited pathogenic variants account for 5% to 10% of all breast cancer (BC) and colorectal cancer (CRC) cases. Here, we sought to profile the pathogenic variants in 25 cancer susceptibility genes in Turkish population. Germline pathogenic variants were screened in 732 BC patients, 189 CRC patients and 490 cancer‐free elderly controls, using next‐generation sequencing‐based multigene panel testing and multiplex ligation‐dependent probe amplification testing. Pathogenic variants were detected in 17.2% of high‐risk BC patients and 26.4% of high‐risk CRC patients. More than 95% of these variants were clinically actionable. BRCA1/2 and mismatch repair genes (MLH1, MSH2 and MSH6) accounted for two‐thirds of all pathogenic variants detected in high‐risk BC and CRC patients, respectively. Pathogenic variants in PALB2, CHEK2, ATM and TP53 were also prevalent in high‐risk BC patients (4.5%). BRCA1 exons 17‐18 deletion and CHEK2 c.592+3A>T were the most common variants predisposing to BC, and they are likely to be founder variants. Three frequent MUTYH pathogenic variants (c.884C>T, c.1437_1439delGGA and c.1187G>A) were responsible for all MUTYH biallelic cases (4.4% of high‐risk CRC patients). The total pathogenic variant frequency was very low in controls (2.4%) and in low‐risk BC (3.9%) and CRC (6.1%) patients. Our study depicts the pathogenic variant spectrum and prevalence in Turkish BC and CRC patients, guiding clinicians and health authorities for genetic testing applications and variant classification in Turkish population.
- 13 July 2020
- Published by Wiley in International Journal of Cancer
- Vol. 148 (2) , 285-295
Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls
Inherited pathogenic variants account for 5% to 10% of all breast cancer (BC) and colorectal cancer (CRC) cases. Here, we sought to profile the pathogenic variants in 25 cancer susceptibility genes in Turkish population. Germline pathogenic variants were screened in 732 BC patients, 189 CRC patients and 490 cancer‐free elderly controls, using next‐generation sequencing‐based multigene panel testing and multiplex ligation‐dependent probe amplification testing. Pathogenic variants were detected in 17.2% of high‐risk BC patients and 26.4% of high‐risk CRC patients. More than 95% of these variants were clinically actionable. BRCA1/2 and mismatch repair genes (MLH1, MSH2 and MSH6) accounted for two‐thirds of all pathogenic variants detected in high‐risk BC and CRC patients, respectively. Pathogenic variants in PALB2, CHEK2, ATM and TP53 were also prevalent in high‐risk BC patients (4.5%). BRCA1 exons 17‐18 deletion and CHEK2 c.592+3A>T were the most common variants predisposing to BC, and they are likely to be founder variants. Three frequent MUTYH pathogenic variants (c.884C>T, c.1437_1439delGGA and c.1187G>A) were responsible for all MUTYH biallelic cases (4.4% of high‐risk CRC patients). The total pathogenic variant frequency was very low in controls (2.4%) and in low‐risk BC (3.9%) and CRC (6.1%) patients. Our study depicts the pathogenic variant spectrum and prevalence in Turkish BC and CRC patients, guiding clinicians and health authorities for genetic testing applications and variant classification in Turkish population.
- Open Access
- 17 July 2018
- Published by Wiley in Clinical Case Reports
- Vol. 6 (9) , 1751-1755
Identification of a BRCA 2 mutation in a Turkish family with early‐onset breast cancer
Key Clinical Message: We used a multi‐gene panel testing to identify the germline variants in a mother‐daughter pair with early‐onset breast cancer, and detected one pathogenic protein‐truncating variant in BRCA 2 . Our results highlight the importance of genetic testing in identifying the pathogenic mutation running in cancer families.
- 17 July 2018
- Published by Wiley in Clinical Case Reports
- Vol. 6 (9) , 1751-1755
Open AccessIdentification of a BRCA 2 mutation in a Turkish family with early‐onset breast cancer
Key Clinical Message: We used a multi‐gene panel testing to identify the germline variants in a mother‐daughter pair with early‐onset breast cancer, and detected one pathogenic protein‐truncating variant in BRCA 2 . Our results highlight the importance of genetic testing in identifying the pathogenic mutation running in cancer families.